Matt Franz : Zealous For Knowledge

Inotek Pharmaceuticals

Inotek Pharmaceuticals is a clinical stage biopharmaceutical company whose only drug candidate, trabodenoson, recently failed. In the wake of the drug’s failure Inotek has suspended all R&D activities and hired Perella Weinberg Partners to explore strategic alternatives.

Inotek’s stock currently trades well below its net asset value (NAV), which provides an opportunity for profit should the company liquidate or sell itself.

My full notes and valuation are here.

This is not a recommendation to buy or sell any stock mentioned. I own shares of Inotek Pharmaceuticals. Do your own research: you are accountable for your own returns. Please read my full disclosure.



Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe: rss | email